Sponsors (2)
The bill expands Medicare coverage for guideline‑based genetic testing, preventive surgeries, and higher‑frequency screening for beneficiaries at hereditary cancer risk—improving early detection and potentially reducing individual treatment burdens—while increasing Medicare spending and creating administrative, access, and implementation challenges.
Medicare beneficiaries with personal or family histories of hereditary cancer gain explicit Medicare coverage for guideline‑based germline mutation testing, increasing access to diagnostic information that can guide prevention and treatment.
Medicare beneficiaries at high genetic or clinical risk gain coverage for evidence‑based risk‑reducing cancer surgeries, which can lower individual cancer risk and improve long‑term health outcomes.
Medicare beneficiaries identified with germline cancer mutations can receive more frequent guideline‑recommended screenings (at least annually) and specified modalities (mammography, breast MRI, colonoscopy, PSA, etc.), improving early detection for high‑risk people.
Expanding coverage for genetic testing, more frequent screening, and preventive surgeries will increase Medicare utilization and federal health spending, which may raise taxpayer costs or pressure other parts of the federal budget.
Requiring contractors to follow the 'least restrictive' guideline when guidelines conflict and relying on guideline interpretation may create administrative complexity, inconsistent local determinations by Medicare Administrative Contractors, and implementation burdens for CMS and providers.
Insurers and providers may face uncertainty and appeals over what testing or procedures conform to guidelines, increasing administrative costs that could be passed to beneficiaries or providers and causing coverage disputes.
Based on analysis of 4 sections of legislative text.
Requires Medicare coverage of guideline-based germline genetic testing, certain risk-reducing surgeries, and more frequent cancer screening for people with hereditary cancer mutations.
Introduced September 10, 2025 by Lisa Murkowski · Last progress September 10, 2025
Requires Medicare to cover evidence-based germline genetic testing for people with personal or family histories that suggest hereditary cancer, sets limits on repeat testing, and directs Medicare to cover guideline-backed risk-reducing surgeries. Also requires Medicare to relax screening frequency limits (to at least annually) and cover additional screening modalities for people found to carry hereditary cancer gene mutations, aligning coverage with recognized oncology clinical practice guidelines.